Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 10/20 | 0.69 |
| ▸ | PDE4A | P27815 | 6/20 | 0.56 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.56 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | APEX1 | P27695 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6692623 | 0.91 | TNF (0.72) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6693277 | 0.87 | TNF (0.77) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL28722625 | 0.83 | TNF (0.72) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6693845 | 0.83 | TNF (0.79) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6688763 | 0.82 | TNF (1.00) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6690149 | 0.81 | TNF (0.59) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6690982 | 0.80 | TNF (0.74) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4863180 | 0.80 | TNF (0.69) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7748783 | 0.77 | TNF (0.62) | TNFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL10926667 | 0.76 | TNF (0.71) | TNFPDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1477486-A2 | Imides as inhibitors of TNF alpha | CELGENE CORPORATION (US) | 2004-11-17 | — | — | EP | claimed |
| US-5605914-A | INHIBITORS OF TUMOR NECROSIS FACTOR | CELGENE CORPORATION (US) | 1997-02-25 | — | — | US | claimed |
| EP-1477486-A2 | Imides as inhibitors of TNF alpha | CELGENE CORPORATION (US) | 2004-11-17 | — | — | EP | disclosed |
| EP-0706521-B1 | IMIDES AS TNF ALPHA INHIBITORS | CELGENE CORP (US) | 2002-10-02 | — | — | EP | disclosed |
| US-6200987-B1 | ADMINISTERING AS TUMOR NECROSIS FACTOR INHIBITORS; CACHEXIA, ENDOTOXIN SHOCK; RETROVIRUS VIRICIDES | CELGENE CORPORATION | 2001-03-13 | — | — | US | disclosed |
| US-6075041-A | TUMOR NECROSIS FACTOR | CELGENE CORPORATION (US) | 2000-06-13 | — | — | US | disclosed |
| EP-1004580-A2 | Imides as inhibitors of TNF alpha | CELGENE CORPORATION (US) | 2000-05-31 | — | — | EP | disclosed |
| EP-1004581-A2 | Process for the preparation of thalidomide | CELGENE CORPORATION (US) | 2000-05-31 | — | — | EP | disclosed |
| EP-1004572-A2 | Amines as inhibitors of TNF alpha | CELGENE CORPORATION (US) | 2000-05-31 | — | — | EP | disclosed |
| US-5877200-A | Cyclic amides | CELGENE CORPORATION (US) | 1999-03-02 | — | — | US | disclosed |
| US-5698579-A | INHIBITOR OF TUMOR NECROSIS FACTOR | CELGENE CORPORATION (US) | 1997-12-16 | — | — | US | disclosed |
| US-5605914-A | INHIBITORS OF TUMOR NECROSIS FACTOR | CELGENE CORPORATION (US) | 1997-02-25 | — | — | US | disclosed |
| EP-0706521-A1 | NOVEL IMIDES | CELGENE CORPORATION (US) | 1996-04-17 | — | — | EP | disclosed |
| WO-1995001348-A2 | IMIDES AS INHIBITORS OF TNP ALPHA | CELGENE CORPORATION (US) | 1995-01-12 | — | — | WO | disclosed |